

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
STARRED QUESTION NO. 187
TO BE ANSWERED ON THE 28TH JULY, 2017
SHORTAGE OF VACCINES**

***187. SHRI R. P. MARUTHARAJAA:**

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Government is aware of the huge shortage of vaccines in the country;
- (b) if so, the details thereof and the reasons therefor;
- (c) whether the Government has any proposal to restart the production of vaccine in three laboratory units-BCG Vaccine Laboratory, Chennai, Pasteur Institute of India, Coonoor and the Central Research Institute, Kasauli;
- (d) if so, the details thereof along with the safety norms being implemented in those units; and
- (e) the time by which the above units are likely to start functioning?

**ANSWER
THE MINISTER OF HEALTH AND FAMILY WELFARE
(SHRI JAGAT PRAKASH NADDA)**

(a) to (e) : A Statement is laid on the Table of the House.

**STATEMENT REFERRED TO IN REPLY TO LOK SABHA
STARRED QUESTION NO. 187* FOR 28TH JULY, 2017**

(a) & (b): There is no shortage of vaccines used for the Universal Immunization Programme of Government of India.

(c) (d) & (e): Yes, the Government has plan to restart production of vaccines in the three vaccine units. The details are as under:

i. Central Research Institute, Kasauli:

The new GMP compliant facility for DPT group of vaccines has been completed and commissioned. The production of DPT Group of Vaccines has already been commenced in the new facility.

ii. BCG Vaccine Laboratory, Chennai:

The new GMP compliant facility for BCG vaccine has been completed and commissioned. Manufacturing of BCG vaccine on trial basis has been successfully completed and commercial production of the same shall start by November, 2017.

iii. Pasteur Institute of India, Coonoor:

The upgradation work for making the facility GMP compliant is underway since August 2013 and expected to be completed by October, 2017. The Performance Qualification and Process validation of new cGMP compliant facility will be commenced from January, 2018 onwards. The trial batch of vaccine production will be carried out from the month of April, 2018 to December, 2018. After that, the commercial production will be commenced from the month of January, 2019.

All safety norms as per cGMP are being enforced in all the three vaccine manufacturing units.
